

- P1-01-01** The blood-tumor barrier as a therapeutic target to improve therapy of brain metastases of breast cancer
Steeg PS, Lyle TR, Paranjapee A, Lockman PR, Duchnowska R, Brastianos PK, Peer C, Figg WD, Pauly GT, Schneider JP, Smith QR, Gril B.
- P1-01-04** Mutational profiling of breast cancer brain metastases - matched pair analysis of next generation sequencing between primary breast cancer and later developed brain metastases
Thulin A, Andersson C, Werner Rönnerman E, De Lara S, Chamalidou C, Schoenfeld A, Kovacs A, Enlund F, Linderholm BK.
- P1-01-06** Targeting the SphK1/S1P/S1PR1 axis that connects obesity, chronic inflammation, and breast cancer metastasis
Nagahashi M, Yamada A, Aoyagi T, Huang W-C, Terracina KP, Hait N, Allegood JC, Tsuchida J, Nakajima M, Katsuta E, Milstient S, Wakai T, Spiegel S, Takabe K
- P1-01-09** BMP4 suppresses the progression of breast cancer through altered expression of metastasis regulating genes
Redfern AD, Eckhardt BL, Cao Y, Sloan EK, Parker BS, Loi S, Ueno NT, Lau PK, Latham B, Anderson RL.
- P1-01-11** The small Rho GTPase Rho A activation mediates the inhibitory effect of microRNA-200b on triple negative breast cancer cell migration and tumor metastasis
Wang Z, Humphries B, Li Y, Yang C.
- P1-01-20** Adjuvant statin therapy efficacy is dictated by tumor dormancy and statin lipophilicity in *ex vivo* and *in vivo* models of metastatic breast cancer
Beckwitt CH, Clark AM, Warita K, Oltvai ZN, Wells A.
- P1-07-04** Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance)
Ligibel JA, Huebner LJ, Rugo HS, Burstein H, Toppmeyer DL, Anders CK, Ma C, Hudis CA, Winer EP, Barry WT.
- P1-07-09** Serum activin A and outcomes in HR+ /HER2- metastatic breast cancer patients treated with everolimus: Results from BOLERO-2
Ali SM, Chen D, Ali A, Krecko L, Leitzel K, Vasekar M, Nagabhairu V, Marks E, Polimera H, Richardson A, May M, He W, Patel P, Lavin M, Hofsess S, Sweetman R, Hortobagyi G, Baselga J, Lipton A
- P1-07-11** Risk factors for the development of brain metastases (BM) in 506 patients with HER2-positive breast cancer (HER2+ BC): A single institutional retrospective analysis
Maurer C, Tulpin L, Dumitrescu C, de Azambuja E, Moreau M, Paesmans M, Nogaret J-M, Piccart M, Awada A.
- P1-07-24** Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A hellenic cooperative oncology group (HeCOG) study.
- P1-07-31** Integrated transcriptomics analyses identify novel three microRNAs signature to predict poor prognosis and metastasis in breast cancer
Takabe K, Kawaguchi T, Yan L, Qi Q, Peng X, Young J, Liu S.
- P1-08-04** Phase I-II trial of pembrolizumab and either doxorubicin (Dox) or an aromatase inhibitor (AI) for triple negative (TN) or hormone receptor positive (HR+) metastatic breast cancer (MBC)
Somlo G, Yuan Y, Waisman J, Yeon C, Frankel P, Hou W, Hurria A, Tank N, Sedrak M, Synold T, Mortimer J, Lee P.

- P1-09-01** A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
Rugo HS, Kabos P, Dickler MN, John WJ, Smith I, Lu Y, Young S, Tolaney SM
- P1-09-05** Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (INO-464), a selective CYP17 lyase and AR inhibitor
Speers CW, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Nyati S, Rae J, Hayes DF, Spratt DE, Wahl DR, Eisner J, Feng FY, Pierce LJ.
- P1-09-06** Blocking ER coregulator signaling enhances CDK4/6 inhibitor palbociclib therapy in ER-positive advanced breast cancer
Viswanadhapalli S, Sareddy GR, Zhou M, Ali E, Li X, Ma S-H, Lee T-K, Tekmal RR, Ahn J-M, Raj GV, Vadlamudi RK
- P1-09-09** Efficacy of estrogen receptor β agonists in the prevention of breast cancer progression to therapy resistance
Ramasamy K, Samayoa C, Krishnegowda NK, Vadlamudi RK, Tekmal RR.
- P1-09-11** A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC)
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat M-J, Poirot C, Paux G, Dubois F, Xuereb L, Robert R, Andre F..
- P1-09-12** mTORC1 is responsible for metastasis of ER+ breast cancer downstream of RON tyrosine kinase
Faham N, Welm A.
- P1-10-02** A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results
Sahota S, Willis A, Kornhauser N, Ward M, Cobham M, Cigler T, Moore A, Andreopoulou E, Fitzpatrick V, Schneider S, Prima N, Wiener A, Ko D, De Laurentiis A, Warren JD, Rubinchik A, Mittal V, Vahdat LT..
- P1-10-04** Elacestrant, a novel oral selective estrogen receptor degrader (SERD), decreases tumoral 18F-FES uptake in a phase 1 study of ER+, HER2 -, advanced breast cancer patients
de Vries EGE, Venema CM, Glaudemans AWJM, Jager A, Menke-van der Houven van Oordt CW, Neven P, Jiang H, Wang D, O'Neill A, Patki A, Aftimos P.
- P1-10-07** Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
Campone M, Sachdev J, Bianchi GV, Beck JT, Martínez-Jáñez N, Cortes J, Schmidt M, Zamagni C, Chen P, Miller J, Fandi A, Gianni L
- P1-11-01** Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC)
Müller V, Jakob A, Aktas B, Grafe A, März W, Fett W, Bruch H-R, Klare P, Hoefflin S, Schneeweiss A.
- P1-14-02** Impact of loco-regional treatment (LRT) on overall-survival (OS) in patients with *de novo* metastatic breast cancer (MBC): Results of the French ESME multicenter national observational programme
Pons-Tostivint EEPT, Kirova YYK, Lusque AAL, Campone MMC, Levy CCL, Delalogue SSD, Mailliez AAM, Madrange NMD, Firmin NNF, Crouzet AAC, Gonçalves AAG, Jankowski CCJ, Lefeuvre CCL, De la Lande BBD, Puget NNP, Bachelot TTB, Ferrero J-MJMF, Uwer LLU, Eymard J-CJCE, Mouret-Reynier M-AMR, Petit TTP, Berchery DDB, Robain MMR, Filleron TTF, Cailliot CCC, Dalenc FFD.

P1-14-04 Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study
La Verde N, Collovà E, Blasi L, Pinotti G, Bernardo A, Bonotto M, Garrone O, Brunello A, Cavazzini MG, Bareggi C, Prochilo T, Porcu L, Moretti A, Barni S,

P1-14-06 Selective internal radiation therapy (SIRT) with Yttrium-90 resin microspheres and FOLFOX/5FU chemotherapy in pre-treated breast cancer patients with liver metastases: A retrospective analysis of response rates, times to progression and survival of patients treated in Manchester UK between 2010 and 2016
Wilson G, Mullamitha S, Bentley D, Bell J, Mullan D, Carter L, Chittalia A, Howell S, Laasch H-U, Westwood T, Jeans S, Tipping J, Ryder D, Farquharson F, Arumugam P, Sheen A, Rajashankar B, Armstrong A, Misra V, Manoharan P, Lawrance J.

P1-16-01 Tumor subtype concordance between breast and bone biopsies in bone only metastasis patients
Parkes AM, Clifton KK, Awadhi A, Oke OC, Warneke CL, Litton JK, Hortobagyi GN.

P1-16-02 Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis
Tahara RK, Fujii T, Saigal B, Ibrahim NK, Damodaran S, Barcenas CH, Murray JL, Chasen BA, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Ueno NT

P1-16-03 An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup
Danson SJ, Perets R, Lopez J, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger B, Pereira KMC, Geva R.

P1-16-05 Incidence of skeletal-related events in patients suffering of bone metastasis from breast cancer treated with bisphosphonates or denosumab
von Heesen A, Nilges K, Radosa J, Gabriel L, Solomayer E-F, Juhasz-Böss I.

P1-17-01 Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsexto

Witzel ID, Laakmann E, Fasching PA, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Zahm D, Blohmer J, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Müller V, Loibl S.

P1-17-02 Ado-trastuzumab emtansine (TDM-1) treatment and brain metastases in HER2 positive metastatic breast cancer patients: Final analysis of an Italian multicenter study

Fabi A, Alesini D, Valle E, Carbognin L, Arpino G, Montemurro F, Ciccarese M, Cannita K, Paris I, Cursano MC, Moscetti L, Ferretti G, De Laurentiis M, Zambelli A, La Verde N, Nisticò C, Gasparro S, Giannarelli D, Cognetti F.

P1-17-03 Abemaciclib for the treatment of brain metastases secondary to hormone receptor positive breast cancer

Bachelot T, Kabos P, Yardley D, Dieras V, Costigan T, Klise S, Awada A.

P1-17-04 Clinical presentation and outcome of leptomeningeal metastasis in patients with breast cancer in relation to histology and tumor subtypes

Griguolo G, Poudroux S, Dieci MV, Jacot W, Bourgier C, Miglietta F, Firmin N, Conte P, Viala M, Guarneri V, Darlix A.

P1-17-05 Prognostic impact of initial treatment modality for brain metastasis in metastatic breast cancer

Kim GM, Cho YU, Kim SI, Park S, Park HS, Kim JY, Chun YJ, Sohn J. Yonsei

P1-17-06 Outcomes of central nervous system radiotherapy for metastatic breast cancer: The Royal Marsden experience 2000 - 2016

Kothari G, De lesa PB, Mohammed K, Ross GM.

P1-17-07 Preclinical characterization of neratinib in a blood-brain barrier co-culture model: Therapeutic implications for breast cancers with brain metastases

Martin TA, Lalani AS, Avogadri Connors F, Bryce RP, Jiang WG.

P1-17-08 Efficacy of lapatinib and capecitabine combination therapy in brain metastases from HER-2 positive metastatic breast cancer: A systematic review and meta-analysis

Thein KZ, Zaw MH, Yendala R, Igid HP, Chai-Adisaksopha C, Hardwicke F, Awasthi S, Radhi S.

P1-17-09 Leptomeningeal disease in ER+HER2- metastatic breast cancer patients: A review of the cases in a single institute over a 14-year period

Watanabe J, Mitsuya K, Hayashi N, Nakasu Y.

P1-17-10 Survival outcomes related to health care coverage in breast cancer patients with brain metastases in Brazil: A sub-analysis from the LACOG-0312 study

Albuquerque C, Debiassi M, Werutsky G, Uema D, Cronenberger E, Cordeiro de Lima VC, de Sant'ana RO, Bines J, Santi PX, Goés RS, Liedke P, Batista MLM, Dybal V, Nerón YV, Beato CA, Borges G, Giacomazzi J, dos Santos LV, Ismael G, Rosa DD, Azambuja A, Andrade D, Martinez-Mesa J, Zaffaroni F, Barrios CH.

Ongoing trials 1

OT1-01-02 A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast
de la Cruz L, Sánchez-Margalet V, Berraondo P, Benito S, Escudero MJ, Caballero R, Carrasco E, Galluzzi L, Rojo F.

OT1-01-03 A phase II multi-center study of BGB324 in combination with pembrolizumab in patients with previously treated, locally advanced and unresectable or metastatic triple negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC)
Yule M, Wnuk-Lipinska K, Davidsen K, Blø M, Hodneland L, Engelsen A, Kang J, Lie M, Bougnaud S, Aguilera K, Ahmed L, Rybicka A, Nævdal EM, Deyna P, Boniecka A, Straume O, Thiery J-P, Chouaib S, Brekken RA, Gausdal G, Lorens JB.

OT1-01-04 A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
O'Day SJ, Stopeck AT, Huhn RD, Gargano MA, Prathikanti R, Ma B, Mattson PM, Lowe JR, Bose N, Ertelt KE, Ottoson NC, Uhlik MT, Graff JR, Chisamore MJ.

OT1-02-01 A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (non-IBC TNBC) who have achieved clinical response or stable disease to prior chemotherapy
Willey JS, Parker CA, Valero V, Lim B, Reuben JM, Krishnamurthy S, Gong Y, Scoggins ME, Dryden MJ, Liu DD, Woodward WA, Ueno NT.

OT1-02-02 A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancer
Barroso-Sousa R, Gao H, Barry WT, Krop IE, Schoenfeld JD, Tolaney SM.

- OT1-03-02** MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors
Baird R, Omlin A, Kiemle-Kallee J, Fiedler U, Zitt C, Feurstein D, Herbst J, Dawson K, vom Baur E, Stumpp M, Hermann F, Harstrick A, Schneeweiss A.
- OT1-03-05** The DETECT V-Study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
Romashova T, Polasik A, Friedl TWP, Rack B, Tzschaschel M, Fasching PA, Taran F-A, Hartkopf A, Schneeweiss A, Mueller V, Bahriye A, Pantel K, Meier-Stiegen F, Wimberger P, Janni W, Fehm T, Huober J.
- OT1-03-06** Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
Shagisultanova E, Diamond J, Stopeck A, Puszta L, O'Regan R, Gradishar W, Brown-Glaberman U, Chalasani P, McSpadden T, Borakove M, Shedin T, Kabos P, Borges V.
- OT1-03-07** Single arm, phase IIA clinical trial assessing the safety and activity of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in patients with metastatic HER-2 positive breast cancer (mHER2+BC)
Goldstein LJ, Obeid E.
- OT1-03-08** A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer
Cascetta KP, Poulidakos P, Shapiro C, Fasano J, Bhardwaj A, Irie H, Goel A, Klein P, Adams S, Kalinsky K, Vahdat L, Ru M, Tiersten A.
- OT1-04-01** Estetrol for treatment of advanced ER+ breast cancer
Verhoeven C, Schmidt M, Hönig A, Dünnebacke J, Dutman E, Krijgh J,
- OT1-04-02** Mifepristone treatment for breast cancer patients expressing levels of progesterone receptor isoform A (PRA) higher than those of isoform B (PRB)
Liguori M, Lanari C, Gass H, Rojas P, Elia A, Martinez Vazquez P, Burruchaga J, Gonzalez P, Caillet Bois I, Ventura C, San Martin G, Castets A, Lovisi S, Acosta Haab G, Lamb C, Fabris V, Novaro V, Molinolo A.
- OT1-05-01** A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer
Santa-Maria CA, Rampurwala M, Wisinski K, Toppmeyer D, O'Regan R.
- OT1-05-02** A phase II clinical trial of the combination of pembrolizumab and selective androgen receptor modulator GTX-024 in patients with advanced androgen receptor positive triple negative breast cancer
Yuan Y, Frankel P, Synold T, Lee P, Yost S, Martinez N, Tang A, Mendez B, Schmolze D, Apple S, Hurria A, Waisman J, Somlo G, Tank N, Sedrak M, Mortimer J.
- OT1-06-03** The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
Turner N, Bye H, Kernaghan S, Proszek P, Fribbens C, Moretti L, Morden J, Snowdon C, Macpherson I, Wardley A, Roylance R, Baird R, Bliss J, Ring A.
- OT1-06-04** [18F] fluoroestradiol (FES) PET as a predictive measure for endocrine therapy in women with newly diagnosed metastatic breast cancer
Linden H, Clark A, Fowler A, Novakova A, Mankoff D, Dehdashti F.

